HUTCHMED (China) Ltd
HCM
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
The best AI stocks to buy now
Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,877.70 | 54.50 | 0.62% |
| CAC 40 | 7,803.33 | 73.64 | 0.95% |
| DAX 40 | 25,087.27 | 280.30 | 1.13% |
| Dow JONES (US) | 51,654.95 | 423.31 | 0.83% |
| FTSE 100 | 10,552.05 | 110.45 | 1.06% |
| HKSE | 24,211.35 | 425.56 | 1.79% |
| NASDAQ | 27,366.17 | 172.83 | 0.64% |
| Nikkei 225 | 69,030.92 | 11.19 | -0.02% |
| NZX 50 Index | 13,749.35 | 57.50 | 0.42% |
| S&P 500 | 7,811.54 | 46.18 | 0.59% |
| S&P/ASX 200 | 8,716.60 | 55.70 | 0.64% |
| SSE Composite Index | 3,813.79 | 1.89 | 0.05% |